Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
Total Valuation
Bolt Biotherapeutics has a market cap or net worth of $8.42M. The enterprise value is $19.67M.
Market Cap$8.42M
Enterprise Value$19.67M
Share Statistics
Bolt Biotherapeutics has 1,921,567 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,921,567
Owned by Insiders2.28%
Owned by Institutions26.23%
Financial Efficiency
Bolt Biotherapeutics’s return on equity (ROE) is -1.26 and return on invested capital (ROIC) is -67.72%.
Return on Equity (ROE)-1.26
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-67.72%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee147.98K
Profits Per Employee-641.85K
Employee Count52
Asset Turnover0.14
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bolt Biotherapeutics is ―. Bolt Biotherapeutics’s PEG ratio is -0.00031.
PE Ratio―
PS Ratio1.33
PB Ratio0.39
Price to Fair Value0.39
Price to FCF-0.26
Price to Operating Cash Flow-0.21
PEG Ratio-0.00031
Income Statement
In the last 12 months, Bolt Biotherapeutics had revenue of 7.70M and earned -33.38M in profits. Earnings per share was -17.85.
Revenue7.70M
Gross Profit6.20M
Operating Income-34.63M
Pretax Income-33.38M
Net Income-33.38M
EBITDA-33.14M
Earnings Per Share (EPS)-17.85
Cash Flow
In the last 12 months, operating cash flow was -39.85M and capital expenditures -72.00K, giving a free cash flow of -39.92M billion.
Operating Cash Flow-39.85M
Free Cash Flow-39.92M
Free Cash Flow per Share-20.78
Dividends & Yields
Bolt Biotherapeutics pays an annual dividend of $0.09, resulting in a dividend yield of ―
Dividend Per Share$0.09
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-45.25%
50-Day Moving Average5.12
200-Day Moving Average5.42
Relative Strength Index (RSI)45.24
Average Volume (3m)29.18K
Important Dates
Bolt Biotherapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Bolt Biotherapeutics as a current ratio of 3.59, with Debt / Equity ratio of 86.62%
Current Ratio3.59
Quick Ratio3.59
Debt to Market Cap0.28
Net Debt to EBITDA-0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bolt Biotherapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bolt Biotherapeutics EV to EBITDA ratio is -0.65, with an EV/FCF ratio of -0.54.
EV to Sales2.79
EV to EBITDA-0.65
EV to Free Cash Flow-0.54
EV to Operating Cash Flow-0.54
Balance Sheet
Bolt Biotherapeutics has $27.50M in cash and marketable securities with $22.96M in debt, giving a net cash position of $4.55M billion.
Cash & Marketable Securities$27.50M
Total Debt$22.96M
Net Cash$4.55M
Net Cash Per Share$2.37
Tangible Book Value Per Share$14.17
Margins
Gross margin is 80.62%, with operating margin of -450.07%, and net profit margin of -433.74%.
Gross Margin80.62%
Operating Margin-450.07%
Pretax Margin-433.74%
Net Profit Margin-433.74%
EBITDA Margin-430.70%
EBIT Margin-450.07%
Analyst Forecast
The average price target for Bolt Biotherapeutics is $41.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$41.00
Price Target Upside836.07% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-46.88%
EPS Growth Forecast34.83%